Showing 881-890 of 1784 results for "".
Managing Brain Metastases Through Multidisciplinary Team Collaboration
https://reachmd.com/programs/cme/managing-brain-metastases-through-multidisciplinary-team-collaboration/56522/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases
https://reachmd.com/programs/cme/first-line-management-of-hrher2-low-breast-cancer-with-brain-metastases/56519/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
https://reachmd.com/programs/cme/gdmt-is-working-fine-so-why-add-more-therapies-for-patients-with-hfref/48811/Which patients with HFrEF may benefit from additional evidence-based therapies beyond GDMT? Join Drs. Lam and Bauersachs in this case-based discussion.Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
https://reachmd.com/programs/cme/missing-the-window-in-ambulatory-patients-with-hfref-on-gdmt-strategies-for-cv-risk-reduction/48813/What is the optimal timing for adding evidence-based therapies beyond GDMT in patients with HFrEF? Explore this topic with Drs. Greene and Savarese.No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
https://reachmd.com/programs/cme/no-patient-with-ckd-left-behind-emerging-ckd-therapies-in-t1d/36524/Gain insights in CKD screening practices, pathophysiology, and treatment from the results of the FINE-1 trial evaluating finerenone in patients with type 1 diabetes.Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
https://reachmd.com/programs/cme/optimizing-outcomes-evidence-based-strategies-for-treating-patients-with-heart-failure-with-mildly-reduced-or-preserved-left-ventricular-ejection-fraction/29905/Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection FractionFrom Pixels to Practice: Advancing HCM Care With Multimodality Imaging
https://reachmd.com/programs/cme/from-pixels-to-practice-advancing-hcm-care-with-multimodality-imaging/39877/Explore how multimodality imaging advances diagnosis, treatment selection, and monitoring in hypertrophic cardiomyopathy care.From Data to Debate: Global Perspectives on HR+/HER2- mBC Care
https://reachmd.com/programs/cme/from-data-to-debate-global-perspectives-on-hrher2-mbc-care/37268/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.The Future of Oral SERDs: Combination Strategies
https://reachmd.com/programs/cme/the-future-of-oral-serds-combination-strategies/39801/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.New Insights in the Management of HCM: Exploring the Clinical Spectrum
https://reachmd.com/programs/cme/new-insights-in-the-management-of-hcm-exploring-the-clinical-spectrum/33026/Explore personalized strategies in obstructive HCM, from diagnosis to treatment evolution, including real-world insights into cardiac myosin inhibitor use.